Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial

Cannabidiol (CBD), a principal phytocannabinoid constituent, has demonstrated antipsychotic properties in recent clinical trials. While it has also been suggested a promising candidate for the treatment of neurodegenerative disorders, it failed to demonstrate efficacy in cognitive impairments associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Leweke, F. Markus, Rohleder, Cathrin, Gerth, Christoph W., Hellmich, Martin, Pukrop, Ralf, Koethe, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117353/
https://www.ncbi.nlm.nih.gov/pubmed/33995015
http://dx.doi.org/10.3389/fphar.2021.614811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117353/
https://www.ncbi.nlm.nih.gov/pubmed/33995015
http://dx.doi.org/10.3389/fphar.2021.614811

Ejemplares similares